Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FSH directly regulates bone mass.

Li Sun1, Yuanzhen Peng, Allison C Sharrow

  • 1Mount Sinai Bone Program, Department of Medicine and Department of Orthopedics, Mount Sinai School of Medicine, New York, NY 10029, USA.

Cell
|April 25, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer.

Cancer letters·2026
Same author

The role of orthoplastic surgery in musculoskeletal oncology.

EFORT open reviews·2025
Same author

Effectiveness of therapeutic exercise and platelet-rich plasma in the case of knee osteoarthritis.

Journal of physical therapy science·2025
Same author

Zinc availability in the tumor microenvironment dictates anti-PD1 response in <i>CDKN2A</i> <sup>Low</sup> tumors via increased macrophage phagocytosis.

bioRxiv : the preprint server for biology·2025
Same author

Identification of the MRTFA/SRF pathway as a critical regulator of quiescence in cancer.

bioRxiv : the preprint server for biology·2024
Same author

Acetate drives ovarian cancer quiescence via ACSS2-mediated acetyl-CoA production.

Molecular metabolism·2024
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
See all related articles
This summary is machine-generated.

Follicle-stimulating hormone (FSH) directly impacts bone loss in hypogonadal states. Elevated FSH, not just low estrogen, drives osteoporosis by promoting osteoclast activity.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Reproductive Biology

Background:

  • Postmenopausal osteoporosis is a major health issue linked to estrogen decline.
  • The role of follicle-stimulating hormone (FSH) in bone metabolism remains unexplored.
  • Rising FSH levels during menopause suggest a potential skeletal function.

Purpose of the Study:

  • To investigate the direct role of FSH in hypogonadal bone loss.
  • To determine if FSH signaling impacts bone resorption independently of estrogen.

Main Methods:

  • Utilized FSHbeta and FSH receptor (FSHR) knockout mice models.
  • Examined bone mass and osteoclast activity in mice with varying FSH levels.
  • Investigated FSHR signaling pathways in osteoclasts and their precursors.

Related Experiment Videos

Main Results:

  • FSH is essential for bone loss in hypogonadal states.
  • FSH receptor (FSHR)-deficient mice showed no bone loss despite hypogonadism.
  • Haploinsufficient FSHbeta+/- mice exhibited increased bone mass and reduced osteoclast resorption.
  • Osteoclasts express functional FSHRs, mediating pro-resorptive signaling pathways.

Conclusions:

  • FSH directly contributes to hypogonadal bone loss.
  • The skeletal effects of FSH are estrogen-independent.
  • Elevated FSH levels may be a key driver of osteoporosis in hypogonadal conditions.